# US 2019/0315761 A1 · Processes for the preparation of (3s,4r)-3-ethyl-4-(3h-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315761 A1
- Document ID: US20190315761A1
- Status: Published application
- Kind: A1
- Application number: 16/453,684
- Filed: 2019-06-26
- Published: 2019-10-17
- Earliest claimed: 2015-10-16
- Assignees: AbbVie Inc.
- Applicants: AbbVie Inc.
- Inventors: Ayman ALLIAN; Jayanthy JAYANTH; Ben KLÜNDER; Mohamed-Eslam F. MOHAMED; Ahmed A. OTHMAN; Patrick J. MARROUM; Peter T. MAYER
- Web page: https://patentgrep.com/patent/US20190315761A1

## CPC

- C07D 487/14: Ortho-condensed systems
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/4985: Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/06: Antipsoriatics
- A61P 17/14: for baldness or alopecia
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C04B 35/62873: {Carbon}
- C04B 35/62886: {by wet chemical techniques}
- C04B 35/64: Burning or sintering processes (C04B33/32 takes precedence {; powder metallurgy B22F})
- C04B 35/657: for manufacturing refractories (C04B35/05, C04B35/107, C04B35/484 take precedence)
- C04B 35/83: Carbon fibres in a carbon matrix
- C07D 487/04: Ortho-condensed systems
- C04B 2235/422: Carbon
- C04B 2235/48: Organic compounds becoming part of a ceramic after heat treatment, e.g. carbonising phenol resins
- C04B 2235/5248: Carbon, e.g. graphite
- C04B 2235/5256: Two-dimensional, e.g. woven structures
- C04B 2235/616: Liquid infiltration of green bodies or pre-forms
- C07B 2200/13: Crystalline forms, e.g. polymorphs
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C04B: LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE {(roofing granules E04D7/005)}; CERAMICS (devitrified glass-ceramics C03C10/00); REFRACTORIES; TREATMENT OF NATURAL STONE
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

## Claims

### Claim at position 1

1-116. (canceled)

### Claim 117

An oral extended release once-daily pharmaceutical composition comprising (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide in an amount sufficient to deliver 15 mg, per unit dosage form, of (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide free base equivalent, wherein administration of a single dose of the oral extended release once-daily pharmaceutical composition to healthy adult subjects results in a mean AUCinf from about 220 ng·hours/mL to about 450 ng·hours/mL of (3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.

### Claim 118 (depends on 117)

The composition of claim 117, wherein the administration is under fasting conditions, and the mean AUCinf is from about 220 ng·hours/mL to about 320 ng·hours/mL.

### Claim 119 (depends on 117)

The composition of claim 117, wherein the administration is under fed conditions, and the mean AUCinf is from about 240 ng·hours/mL to about 450 ng·hours/mL.

### Claim 120 (depends on 117)

The composition of claim 117, wherein the difference in the mean AUCinf under fed conditions versus fasting conditions is about 30% or less.

### Claim 121 (depends on 117)

The composition of claim 117, wherein the administration results in a mean Cmax from about 25 ng/mL to about 70 ng/mL.

### Claim 122 (depends on 121)

The composition of claim 121, wherein the administration is under fasting conditions, and the mean Cmax is from about 25 ng/mL to about 40 ng/mL.

### Claim 123 (depends on 121)

The composition of claim 121, wherein the administration is under fasting conditions, and the mean Cmax is from about 25 ng/mL to about 30 ng/mL.

### Claim 124 (depends on 121)

The composition of claim 121, wherein the difference in the mean Cmax under fed conditions versus fasting conditions is about 30% or less.

### Claim 125 (depends on 120)

The composition of claim 120, wherein the administration results in a mean Cmax from about 25 ng/mL to about 70 ng/mL.

### Claim 126 (depends on 125)

The composition of claim 125, wherein the administration is under fasting conditions, and the mean Cmax is from about 25 ng/mL to about 40 ng/mL.

### Claim 127 (depends on 125)

The composition of claim 125, wherein the administration is under fasting conditions, and the mean Cmax is from about 25 ng/mL to about 30 ng/mL.

### Claim 128 (depends on 125)

The composition of claim 125, wherein the difference in the mean Cmax under fed conditions versus fasting conditions is about 30% or less.

### Claim 129 (depends on 117)

The composition of claim 117, wherein the administration results in a mean Tmax from about 2.0 to about 4.0 hours.

### Claim 130 (depends on 129)

The composition of claim 129, wherein the administration is under fasting conditions, and the mean Tmax is about 3.0 hours.

### Claim 131 (depends on 117)

The composition of claim 117, wherein the administration results in a mean Cmax from about 25 ng/mL to about 70 ng/mL, and a mean Tmax from about 2.0 to about 4.0 hours.

### Claim 132 (depends on 117)

The composition of claim 117, wherein (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide is a free base crystalline hemihydrate.

### Claim 133 (depends on 132)

The composition of claim 132, wherein the free base crystalline hemihydrate has an X-ray powder diffraction pattern characterized by peaks at 13.4±0.2, 15.1±0.2, and 21.7±0.2 degrees two theta when measured at about 25° C. with monochromatic Kα1 radiation.

### Claim 134 (depends on 132)

The composition of claim 132, wherein the free base crystalline hemihydrate is Freebase Hydrate Form C.

### Claim 135

An oral extended release once-daily pharmaceutical composition comprising (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide in an amount sufficient to deliver 15 mg, per unit dosage form, of (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide free base equivalent, wherein administration of a single dose of the oral extended release once-daily pharmaceutical composition to healthy adult subjects results in a mean Cmax from about 25 ng/mL to about 70 ng/mL of (3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.

### Claim 136 (depends on 135)

The composition of claim 135, wherein the administration is under fasting conditions, and the mean Cmax is from about 25 ng/mL to about 40 ng/mL.

### Claim 137 (depends on 135)

The composition of claim 135, wherein the administration is under fasting conditions, and the mean Cmax is from about 25 ng/mL to about 30 ng/mL.

### Claim 138 (depends on 135)

The composition of claim 135, wherein the difference in the mean Cmax under fed conditions versus fasting conditions is about 30% or less.

### Claim 139 (depends on 135)

The composition of claim 135, wherein the administration results in a mean Tmax from about 2.0 to about 6.0 hours.

### Claim 140 (depends on 139)

The composition of claim 139, wherein the administration results in a mean Tmax of about 3.0 hours.

### Claim 141 (depends on 135)

The composition of claim 135, wherein (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide is a free base crystalline hemihydrate.

### Claim 142 (depends on 141)

The composition of claim 141, wherein the free base crystalline hemihydrate has an X-ray powder diffraction pattern characterized by peaks at 13.4±0.2, 15.1±0.2, and 21.7±0.2 degrees two theta when measured at about 25° C. with monochromatic Kα1 radiation.

### Claim 143 (depends on 141)

The composition of claim 141, wherein the free base crystalline hemihydrate is Freebase Hydrate Form C.

### Claim 144

An oral extended release once-daily pharmaceutical composition comprising (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide in an amount sufficient to deliver 15 mg, per unit dosage form, of (3 S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide free base equivalent, wherein the oral extended release once-daily pharmaceutical composition is bioequivalent to an oral extended release once-daily film-coated tablet consisting of:
(i) in the intragranular core: 15.4 mg of Freebase Hydrate Form C, 40.0 mg of microcrystalline cellulose, and 4.8 mg of hydroxypropyl methyl cellulose;
(ii) in the extragranular core: 122.5 mg of Microcrystalline cellulose, 100.6 mg of mannitol, 96.0 mg of tartaric acid, 91.2 mg of hydroxypropyl methyl cellulose, 2.4 mg of colloidal silicon dioxide/silica, and 7.2 mg of magnesium stearate; and
(iii) 14.4 mg of a film coat comprising polyvinyl alcohol, titanium dioxide, polyethylene glycol 3350, talc, and iron oxide.
